Back to Journals » Psoriasis: Targets and Therapy » Volume 16 » default
Psoriasis: Targets and Therapy
- View all (214)
- Volume 16, 2026 (10)
- Volume 15, 2025 (48)
- Volume 14, 2024 (23)
- Volume 13, 2023 (7)
- Volume 12, 2022 (22)
- Volume 11, 2021 (14)
- Volume 10, 2020 (8)
- Volume 9, 2019 (13)
- Volume 8, 2018 (12)
- Volume 7, 2017 (9)
- Volume 6, 2016 (15)
- Volume 5, 2015 (13)
- Volume 4, 2014 (5)
- Volume 3, 2013 (4)
- Volume 2, 2012 (10)
- Volume 1, 2011 (1)
Archive: Volume 16, 2026
Patient-Reported Well-Being in Value-Based Routine Care in Psoriatic Disease Using Tildrakizumab: 2-Year Data of the Phase IV POSITIVE Study
Mrowietz U, Sommer R, Reguiai Z, Gerdes S, Daudén E, Weger W, Maul JT, Naldi L, Ghislain PD, Laws PM, De Jong EMGJ, Mburu S, Koscielny V, Massana E, Sapena V, Domenech A, Kasujee I, Augustin M
Psoriasis: Targets and Therapy 2026, 16:590189
Published Date: 12 May 2026
Genetic Evidence Linking Immune Cell Subsets to Psoriatic Arthritis Susceptibility: A Mendelian Randomization Study
Wang H, Ma M, Wang C, Zhen Y, Li S
Psoriasis: Targets and Therapy 2026, 16:589733
Published Date: 16 April 2026
Core Differentially Expressed Genes in Psoriasis Lesions: An Integrated Analysis of Four GEO Datasets
Ennouri M, Görmez Z, Bahloul E, Becha MK, Elleuch NB, Inal-Gültekin G
Psoriasis: Targets and Therapy 2026, 16:580680
Published Date: 3 April 2026
Application of Trichoscopy and Novel Non-Invasive Imaging Techniques in the Diagnosis and Management of Patients with Scalp Psoriasis
Kuchnicka A, Fałkowska U, Konopelski P, Anderson A, Rakowska A, Kurzeja M, Olszewska M, Rudnicka L
Psoriasis: Targets and Therapy 2026, 16:549372
Published Date: 30 March 2026
Indole-3-Lactic Acid Attenuates IMQ-Induced Psoriasiform Dermatitis in Mice via AhR-Dependent Suppression of IL-17A
Meng Z, Ren J, Lai Y, Lu S, Wu H, Jiang Y, Zhang Z, Tan G, Shi Z
Psoriasis: Targets and Therapy 2026, 16:585731
Published Date: 27 March 2026
The Psoriatic Disease Assessment Index (PSODAI) Score to Evaluate Systemic Involvement of Psoriasis
Liang Y, Deng B, Ntawuyamara E, Bachelez H, Wang F, Zhang H, Zhang Z, Li Z, Dang L, Wang Y, Zou X, Wang L, Duan D, Chen H, Zheng W, Huang H, Zhang M, Cai Q, Chen Y, Zhang Y, Lu Z, Ren Y, Huang J
Psoriasis: Targets and Therapy 2026, 16:548700
Published Date: 16 February 2026
Persistence and Long-Term Disease Control of Interleukin-17 Inhibitors and Interleukin-23 Inhibitors in Patients with Psoriasis: A Nationwide Cohort Study in Japan
Xu Y, Li T, Chang CL, Zhang Y, Masuda J, Wu GHM, Wahking B, Imafuku S, Qiu H
Psoriasis: Targets and Therapy 2026, 16:565823
Published Date: 11 February 2026
Prevalence of Genital Psoriasis and Its Impact on Patients’ Sexual Life in Routine Care: Epidemiologic Survey in Germany
Janke TM, Sorbe C, Sommer R, Bickert T, Mrowietz U, Gomis-Kleindienst S, Schild M, Lohmann K, Augustin M
Psoriasis: Targets and Therapy 2026, 16:516803
Published Date: 21 January 2026
Bidirectional Associations Between Substance Abuse and Psoriasis: A Prospective Cohort Study
Che X, Zhou J, Wang A, Guo J, Zhang C, Xiao Y
Psoriasis: Targets and Therapy 2026, 16:557781
Published Date: 7 January 2026
Successful Treatment of Two Rare Pediatric Keratinization Disorders with Secukinumab: Epidermolytic Ichthyosis and PRP–GPP Overlap
Xu Q, Zhang J
Psoriasis: Targets and Therapy 2026, 16:553794
Published Date: 6 January 2026
